We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 944

Trademark rights and protection in Australia
  • Davies Collison Cave
  • Australia, Global
  • September 4 2018

A structured to trademark rights and protection in Australia


Trademarks in Australia
  • Davies Collison Cave
  • Australia, Global
  • September 4 2018

A structured guide to Trademark laws in Australia


Patent Owner Must Pay Accused Infringer’s $14 Million Attorney Fees and Costs Because of Prosecution and Litigation Misconduct
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • July 24 2018

A New Jersey court ordered a patent owner to pay $14 million to a company it sued for patent infringement to reimburse that company for its


Insights: Alerts USPTO Guidance on Subject Matter Eligibility of Method of Treatment Claims
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • June 20 2018

On June 7, 2018, the USPTO issued a memorandum to patent examiners based on the recent Federal Circuit decision in Vanda Pharmaceuticals Inc. v


Nearly All Post-Alice Eligibility Rejections are Affirmed in Whole by the PTAB
  • Kilpatrick Townsend & Stockton LLP
  • USA
  • May 28 2018

Frequently, the fate of a patent application lies with a single patent examiner. This power frustrates applicants when an impasse has been reached in


Are Combined Diagnosis and Treatment Still Patent-Eligible? One Court Says “No”
  • Bradley Arant Boult Cummings LLP
  • USA
  • April 24 2018

In 2011 the Supreme Court announced that methods of diagnosing disease are ineligible for patenting under its landmark decision, Mayo Collaborative


USPTO issues memo clarifying written description guidance for claims to antibodies
  • White & Case LLP
  • USA
  • March 22 2018

Citing Amgen v. Sanofi, 872 F.3d 1367, 1378-79 (Fed. Cir. 2017), the USPTO advises that "when an antibody is claimed, 35 U.S.C. 112(a) requires


Guidance from Recent PTAB Expanded Panels on Serial Petitions
  • Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • USA
  • October 13 2017

In a rare occurrence, the Chief Judge and deputy Chief Judge of the Patent Trial and Appeal Board (PTAB) joined panels issuing decisions on the same


PTAB Warns Petitioners That Follow-On Petitions Will Face Additional Scrutiny
  • Morgan Lewis
  • USA
  • September 28 2017

A recent expanded panel decision, which lists factors the PTAB will use in exercising its discretion to institute serial IPR petitions, is afforded an


Federal Circuit Says PTO Submissions can Waive Privilege to Future Communications
  • Mintz
  • USA
  • August 15 2017

On July 20, 2017, the United States Court of Appeals for the Federal Circuit in In re OptumInsight denied OptumInsight’s petition for writ of mandamus